BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292. [PMID: 27087015 DOI: 10.1111/apt.13633] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 15.8] [Reference Citation Analysis]
Number Citing Articles
1 Gabr SA, Alghadir AH. Handgrip Strength and Vitamin D as Predictors of Liver Fibrosis and Malnutrition in Chronic Hepatitis C Patients. Dis Markers 2021;2021:6665893. [PMID: 33884041 DOI: 10.1155/2021/6665893] [Reference Citation Analysis]
2 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Reference Citation Analysis]
3 Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2017;15:349-59. [PMID: 27840182 DOI: 10.1016/j.cgh.2016.10.034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
4 Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, Hosry J, Shigle TL, Kaseb A, Torres HA. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther 2016;44:1235-41. [PMID: 27730654 DOI: 10.1111/apt.13825] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
5 Mehta V, Mahajan R, Midha V, Narang V, Kaur K, Singh A, Malhotra A, Parvez A, Sood A. Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India. J Clin Exp Hepatol 2018;8:7-14. [PMID: 29743791 DOI: 10.1016/j.jceh.2017.06.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Buti M, Calleja JL, Lens S, Diago M, Ortega E, Crespo J, Planas R, Romero-Gómez M, Rodríguez FG, Pascasio JM, Fevery B, Kurland D, Corbett C, Kalmeijer R, Jessner W. Simeprevir in combination with sofosbuvir in treatment-naïve and -experienced patients with hepatitis C virus genotype 4 infection: a Phase III, open-label, single-arm study (PLUTO). Aliment Pharmacol Ther 2017;45:468-75. [PMID: 27896822 DOI: 10.1111/apt.13883] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
7 Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421-431. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
8 Takata R, Nishikawa H, Enomoto H, Iwata Y, Ishii A, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Relationship between skeletal muscle mass and liver fibrosis markers for patients with hepatitis C virus related liver disease. Medicine (Baltimore) 2017;96:e8761. [PMID: 29310350 DOI: 10.1097/MD.0000000000008761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Elzorkany K, Kora MA, Wahed ASA, Zaghla HE, Zahran AM, Yassein YS, El Naggar AZ, Essa A, Gadallah AA. Assessment of Renal Function in Post-Liver Transplant HCV-Positive Patients Treated with Direct Acting Antivirals. Int J Nephrol Renovasc Dis 2020;13:351-8. [PMID: 33273842 DOI: 10.2147/IJNRD.S275721] [Reference Citation Analysis]
10 Kiang TKL. Clinical Pharmacokinetics and Drug-Drug Interactions of Elbasvir/Grazoprevir. Eur J Drug Metab Pharmacokinet 2018;43:509-31. [PMID: 29557529 DOI: 10.1007/s13318-018-0471-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Tahmoorespur M, Azghandi M, Javadmanesh A, Meshkat Z, Sekhavati MH. A Novel Chimeric Anti-HCV Peptide Derived from Camel Lactoferrin and Molecular Level Insight on Its Interaction with E2. Int J Pept Res Ther 2020;26:1593-605. [DOI: 10.1007/s10989-019-09972-7] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
12 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
13 Andreoni M, Babudieri S, Bruno S, Colombo M, Zignego AL, Di Marco V, Di Perri G, Perno CF, Puoti M, Taliani G, Villa E, Craxì A. Current and future challenges in HCV: insights from an Italian experts panel. Infection 2018;46:147-63. [PMID: 29098647 DOI: 10.1007/s15010-017-1093-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Butt AA, Yan P, Simon TG, Abou-Samra AB. Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES. Clin Infect Dis. 2017;65:1006-1011. [PMID: 28903508 DOI: 10.1093/cid/cix364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
15 Kemp L, Clare KE, Brennan PN, Dillon JF. New horizons in hepatitis B and C in the older adult. Age Ageing 2019;48:32-7. [PMID: 30379991 DOI: 10.1093/ageing/afy170] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Guerra Veloz MF, Del Pino Bellido P, Cordero Ruiz P, Vega Rodriguez F, Bellido Muñoz F, Ramirez de Arellano E, Caunedo Álvarez A, Pascual Hernandez A, Carmona Soria I. HCV microelimination strategies: An interventional study in diagnosed patients without access to the system. Liver Int 2021;41:928-33. [PMID: 33587789 DOI: 10.1111/liv.14824] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
18 Kozbial K, Aberle SW, Susser S, Al-zoairy R, Moser S, Stättermayer AF, Maieron A, Gschwantler M, Stauber R, Graziadei I, Zoller H, Beinhardt S, Holzmann H, Munda-steindl P, Hofer H, Sarrazin C, Ferenci P. Letter: retreatment of patients with chronic hepatitis C who have failed interferon-free combination therapy with direct acting anti-virals. Aliment Pharmacol Ther 2017;45:373-5. [DOI: 10.1111/apt.13887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Open Forum Infect Dis 2019;6:ofz185. [PMID: 31123693 DOI: 10.1093/ofid/ofz185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
20 Abdulsamad M, Ihimoyan A. Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side Effect. Case Reports Hepatol 2016;2016:8627139. [PMID: 28044114 DOI: 10.1155/2016/8627139] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
21 Li Z, Yao F, Xue G, Xu Y, Niu J, Cui M, Wang H, Wu S, Lu A, Zhong J, Meng G. Antiviral effects of simeprevir on multiple viruses. Antiviral Res 2019;172:104607. [PMID: 31563599 DOI: 10.1016/j.antiviral.2019.104607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
22 Fialho R, Pereira M, Harrison N, Rusted J, Whale R. Co-infection with HIV associated with reduced vulnerability to symptoms of depression during antiviral treatment for hepatitis C. Psychiatry Res 2017;253:150-7. [PMID: 28365538 DOI: 10.1016/j.psychres.2017.03.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
23 Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, Hatakeyama K, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. Cancer Med 2022. [PMID: 35174643 DOI: 10.1002/cam4.4571] [Reference Citation Analysis]
24 Sugiura A, Joshita S, Umemura T, Yamazaki T, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Usami Y, Wada S, Mori H, Shibata S, Yoshizawa K, Morita S, Furuta K, Kamijo A, Iijima A, Kako S, Maruyama A, Kobayashi M, Komatsu M, Matsumura M, Miyabayashi C, Ichijo T, Takeuchi A, Koike Y, Gibo Y, Tsukadaira T, Inada H, Kiyosawa K, Tanaka E. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. J Viral Hepat 2018;25:1462-71. [DOI: 10.1111/jvh.12973] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
25 Toyoda H, Hiraoka A, Uojima H, Nozaki A, Shimada N, Takaguchi K, Abe H, Atsukawa M, Matsuura K, Ishikawa T, Mikami S, Watanabe T, Itobayashi E, Tsuji K, Arai T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Okubo T, Ehira T, Kumada T, Tanaka J. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response. Hepatol Commun 2021;5:1290-9. [PMID: 34278176 DOI: 10.1002/hep4.1716] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Eletreby R, El-Serafy M, Anees M, Kasem G, Salama M, Elkhouly R, Hamdy M, Abdel Haleem H, Kamal E, Abdel-Razek W, Salama R, Elshenawy M, Shafeek A, Hassany M, El-Sayed MH, El-Shazly Y, Esmat G. Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Liver Int 2020;40:797-805. [PMID: 31858694 DOI: 10.1111/liv.14299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
27 Bandiera S, Billie Bian C, Hoshida Y, Baumert TF, Zeisel MB. Chronic hepatitis C virus infection and pathogenesis of hepatocellular carcinoma. Curr Opin Virol. 2016;20:99-105. [PMID: 27741441 DOI: 10.1016/j.coviro.2016.09.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
28 Mogalian E, Brainard DM, Osinusi A, Moorehead L, Murray B, Ling KHJ, Perry R, Curtis C, Lawitz E, Lasseter K, Marbury T, Mathias A. Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Clin Pharmacokinet 2018;57:1449-57. [DOI: 10.1007/s40262-018-0645-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
29 Kawaguchi T, Ide T, Koga H, Kondo R, Miyajima I, Arinaga-Hino T, Kuwahara R, Amano K, Niizeki T, Nakano M, Kuromatsu R, Torimura T. Rapidly growing hepatocellular carcinoma after direct-acting antiviral treatment of chronic hepatitis C. Clin J Gastroenterol 2018;11:69-74. [PMID: 29082453 DOI: 10.1007/s12328-017-0789-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
30 Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66:1173-1181. [PMID: 28161470 DOI: 10.1016/j.jhep.2017.01.020] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 20.0] [Reference Citation Analysis]
31 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
32 European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
33 Shalaby S, Zanetto A, Vitale A, Gambato M, Cillo U, Farinati F, Burra P, Russo FP. Reply. Liver Transpl 2017;23:1630-1. [PMID: 29024423 DOI: 10.1002/lt.24956] [Reference Citation Analysis]
34 Hamana A, Takahashi Y, Uchida T, Nishikawa M, Imamura M, Chayama K, Takakura Y. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus. Antiviral Res 2017;146:130-8. [PMID: 28864074 DOI: 10.1016/j.antiviral.2017.08.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
35 Terrault NA, Hassanein TI. Management of the patient with SVR. Journal of Hepatology 2016;65:S120-9. [DOI: 10.1016/j.jhep.2016.08.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
36 Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Clin Mol Hepatol 2017;23:74-9. [PMID: 28259115 DOI: 10.3350/cmh.2016.0052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
37 Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, Aizaki H, Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T. Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. J Gen Virol 2020;101:188-97. [PMID: 31859613 DOI: 10.1099/jgv.0.001378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
38 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
39 Rewisha E, Salman T, Alhaddad O, Raia GA, Naguib M, Rashad S, Abdelfattah A, Metwally K, Abdelsameea E. Hyaluronic acid as a potential marker for assessment of fibrosis regression after direct acting antiviral drugs in chronic hepatitis C patients. Clin Exp Hepatol 2021;7:320-7. [PMID: 34712835 DOI: 10.5114/ceh.2021.109293] [Reference Citation Analysis]
40 El Sherif O, Afhdal N, Curry M. No one size fits all-Shortening duration of therapy with direct-acting antivirals for hepatitis C genotype 1 infection. J Viral Hepat 2017;24:808-13. [PMID: 28581634 DOI: 10.1111/jvh.12734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
41 Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf 2018;17:235-41. [PMID: 29325476 DOI: 10.1080/14740338.2018.1424829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
42 Higuchi M, Tamaki N, Kurosaki M, Inada K, Kirino S, Yamashita K, Hayakawa Y, Sekiguchi S, Osawa L, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Enomoto N, Izumi N. Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. J Med Virol 2021;93:3744-51. [PMID: 32890408 DOI: 10.1002/jmv.26490] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Schütte K, Balbisi F, Malfertheiner P. Prevention of Hepatocellular Carcinoma. Gastrointest Tumors 2016;3:37-43. [PMID: 27722155 DOI: 10.1159/000446680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
44 Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, Soria A, Raimondo G, Filomia R, Di Leo A, Iannone A, Massari M, Corsini R, Gulminetti R, Gatti Comini A, Toniutto P, Dissegna D, Russo FP, Zanetto A, Rumi MG, Brancaccio G, Danieli E, Brunetto MR, Weimer LE, Quaranta MG, Vella S, Puoti M. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One 2017;12:e0172159. [PMID: 28245248 DOI: 10.1371/journal.pone.0172159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
45 Štekláč M, Zajaček D, Bučinský L. 3CLpro and PLpro affinity, a docking study to fight COVID19 based on 900 compounds from PubChem and literature. Are there new drugs to be found? J Mol Struct 2021;1245:130968. [PMID: 34219808 DOI: 10.1016/j.molstruc.2021.130968] [Reference Citation Analysis]
46 Lee J, Ou JJ. Hepatitis C virus and intracellular antiviral response. Curr Opin Virol 2021;52:244-9. [PMID: 34973476 DOI: 10.1016/j.coviro.2021.12.010] [Reference Citation Analysis]
47 Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166:637-648. [PMID: 28319996 DOI: 10.7326/m16-2575] [Cited by in Crossref: 327] [Cited by in F6Publishing: 148] [Article Influence: 65.4] [Reference Citation Analysis]
48 McDonald SA, Pollock KG, Barclay ST, Goldberg DJ, Bathgate A, Bramley P, Dillon JF, Fraser A, Innes HA, Kennedy N, Morris J, Went A, Hayes PC, Hutchinson SJ. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis. J Viral Hepat 2020;27:270-80. [PMID: 31696575 DOI: 10.1111/jvh.13232] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
49 Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD, Workowski KA, Pearlman B, Hyland RH, Stamm LM, Svarovskaia E, Dvory-Sobol H, Zhu Y, Subramanian GM, Brainard DM, McHutchison JG, Bräu N, Berg T, Agarwal K, Bhandari BR, Davis M, Feld JJ, Dore GJ, Stedman CAM, Thompson AJ, Asselah T, Roberts SK, Foster GR. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology 2017;153:113-22. [PMID: 28390869 DOI: 10.1053/j.gastro.2017.03.047] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 34.0] [Reference Citation Analysis]
50 Butt AA, Yan P, Marks K, Shaikh OS, Sherman KE; ERCHIVES Study Team. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Aliment Pharmacol Ther 2016;44:728-37. [PMID: 27459341 DOI: 10.1111/apt.13748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
51 Merchante N, Rodríguez-Arrondo F, Revollo B, Merino E, Ibarra S, Galindo MJ, Montero M, García-Deltoro M, Rivero-Juárez A, Téllez F, Delgado-Fernández M, Ríos-Villegas MJ, García MA, Vera-Méndez FJ, Ojeda-Burgos G, López-Ruz MA, Metola L, Omar M, Alemán-Valls MR, Aguirrebengoa K, Portu J, Raffo M, Macías J, Pineda JA; GEHEP-002 Study Group. Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients. AIDS 2018;32:1423-30. [PMID: 29596108 DOI: 10.1097/QAD.0000000000001809] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
52 Bladowska J, Pawłowski T, Fleischer-Stępniewska K, Knysz B, Małyszczak K, Żelwetro A, Rymer W, Inglot M, Waliszewska-Prosół M, Ejma M, Podgórski P, Zimny A, Sąsiadek M. Interferon-free therapy as the cause of white matter tracts and cerebral perfusion recovery in patients with chronic hepatitis C. J Viral Hepat 2019;26:635-43. [PMID: 30702208 DOI: 10.1111/jvh.13069] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
53 Waliszewska-Prosół M, Bladowska J, Ejma M, Fleischer-Stępniewska K, Rymer W, Sąsiadek M, Pawłowski T, Małyszczak K, Inglot M, Żelwetro A, Podgórski P, Knysz B. Visual and brainstem auditory evoked potentials in HCV-infected patients before and after interferon-free therapy - A pilot study. Int J Infect Dis 2019;80:122-8. [PMID: 30641198 DOI: 10.1016/j.ijid.2019.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol 2016;9:1413-21. [PMID: 27603877 DOI: 10.1080/17512433.2016.1233813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
55 Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6:79-84. [PMID: 29607308 DOI: 10.14218/jcth.2017.00067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
56 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176. [PMID: 28404132 DOI: 10.1016/s2468-1253(16)30181-9] [Cited by in Crossref: 1051] [Cited by in F6Publishing: 472] [Article Influence: 175.2] [Reference Citation Analysis]
57 Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, Berg T, Spengler U, Weiland O, van der Valk M, Rockstroh J, Peck-Radosavljevic M, Zhao Y, Jimenez-Exposito MJ, Zeuzem S. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016;65:1861-70. [PMID: 27605539 DOI: 10.1136/gutjnl-2016-312444] [Cited by in Crossref: 130] [Cited by in F6Publishing: 127] [Article Influence: 21.7] [Reference Citation Analysis]
58 Muñoz-Hernández R, Ampuero J, Millán R, Gil-Gómez A, Rojas Á, Macher HC, Gallego-Durán R, Gato S, Montero-Vallejo R, Rico MC, Maya-Miles D, Sánchez-Torrijos Y, Soria IC, Stiefel P, Romero-Gómez M. Hepatitis C Virus Clearance by Direct-Acting Antivirals Agents Improves Endothelial Dysfunction and Subclinical Atherosclerosis: HEPCAR Study. Clin Transl Gastroenterol 2020;11:e00203. [PMID: 32955194 DOI: 10.14309/ctg.0000000000000203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
59 Ampuero J, Jimeno C, Quiles R, Rosales JM, Llerena S, Palomo N, Cordero P, Serrano FJ, Urquijo JJ, Moreno-Planas JM, Ontanilla G, Hernández M, Ortega-Alonso A, Maraver M, Bonacci M, Rojas Á, Figueruela B, Forns X, Andrade RJ, Calleja JL, Diago M, Carmona I, de la Mata M, Buti M, Crespo J, Pascasio JM, Navarro JM, Salmerón J, Romero-Gómez M. Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C. J Hepatol 2018;68:940-8. [PMID: 29288753 DOI: 10.1016/j.jhep.2017.12.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
60 Posthuma CC, Te Velthuis AJW, Snijder EJ. Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes. Virus Res 2017;234:58-73. [PMID: 28174054 DOI: 10.1016/j.virusres.2017.01.023] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 12.4] [Reference Citation Analysis]
61 George N, Harrell SM, Rhodes KD, Duarte-Rojo A. Recreational Drug and Psychosocial Profile in Chronic Hepatitis C Patients Seeking Antiviral Therapy. Ann Hepatol 2018;17:76-84. [PMID: 29311404 DOI: 10.5604/01.3001.0010.7537] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Prenner SB, Kulik L. Hepatocellular carcinoma in the wait-listed patient with hepatitis C virus. Curr Opin Organ Transplant 2018;23:237-43. [PMID: 29406448 DOI: 10.1097/MOT.0000000000000505] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Yin P, Zhang L, Ye F, Deng Y, Lu S, Li YP, Zhang L, Tan W. A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2. Sci Rep 2017;7:3976. [PMID: 28638089 DOI: 10.1038/s41598-017-04274-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
64 Shen Y, Shi Z, Yan B. Carboxylesterases: Pharmacological Inhibition Regulated Expression and Transcriptional Involvement of Nuclear Receptors and other Transcription Factors. Nuclear Receptor Research 2019;6. [DOI: 10.32527/2019/101435] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
65 Bonaventura A, Montecucco F. Sofosbuvir/velpatasvir: A promising combination. World J Hepatol 2016; 8(19): 785-789 [PMID: 27429714 DOI: 10.4254/wjh.v8.i19.785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
66 Al Khayat MNMT, Eijsink JFH, Postma MJ, Wilschut JC, van Hulst M. The Cost-Effectiveness of Hepatitis C Virus Screening Strategies among Recently Arrived Migrants in the Netherlands. Int J Environ Res Public Health 2020;17:E6091. [PMID: 32825680 DOI: 10.3390/ijerph17176091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Choi GH, Jang ES, Kim JW, Jeong SH. A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea. Gut Liver 2020;14:808-16. [PMID: 32066209 DOI: 10.5009/gnl19296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017;42:14-23. [PMID: 28379888 DOI: 10.1097/01.NPR.0000515423.38284.28] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
69 Peschel G, Moleda L, Baier L, Selgrad M, Schmid S, Scherer MN, Müller M, Weigand K. Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study. Transplant Proc 2018;50:1444-50. [PMID: 29880368 DOI: 10.1016/j.transproceed.2018.02.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Endo K, Sato T, Suzuki A, Yoshida Y, Kakisaka K, Miyasaka A, Takikawa Y. Sustained virologic response by direct-acting antivirals suppresses skeletal muscle loss in hepatitis C virus infection. J Gastroenterol Hepatol. 2020;35:1602-1609. [PMID: 31975438 DOI: 10.1111/jgh.14991] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
71 Marciano S, Haddad L, Plazzotta F, Mauro E, Terraza S, Arora S, Thornton K, Ríos B, García Dans C, Ratusnu N, Calanni L, Allevato J, Sirotinsky ME, Pedrosa M, Gadano A. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C. J Med Virol 2017;89:660-4. [PMID: 27551942 DOI: 10.1002/jmv.24668] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
72 Goutzamanis S, Doyle J, Higgs P, Hellard M. Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience. J Viral Hepat 2019;26:218-23. [PMID: 30315689 DOI: 10.1111/jvh.13020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018;38:1295-331. [PMID: 29149530 DOI: 10.1002/med.21475] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
74 Eijsink JFH, Al Khayat MNMT, Boersma C, Ter Horst PGJ, Wilschut JC, Postma MJ. Cost-effectiveness of hepatitis C virus screening, and subsequent monitoring or treatment among pregnant women in the Netherlands. Eur J Health Econ 2021;22:75-88. [PMID: 33064259 DOI: 10.1007/s10198-020-01236-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska K, Piekarska A, Tronina O, Madej G, Garlicki A, Lucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski M, Horban A, Knysz B, Tudrujek M, Halota W, Simon K. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther 2016;44:946-56. [PMID: 27611776 DOI: 10.1111/apt.13790] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
76 Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Adv Med Sci 2017;62:387-92. [PMID: 28554119 DOI: 10.1016/j.advms.2017.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
77 Mücke VT, Thomas D, Mücke MM, Waidmann O, Zeuzem S, Sarrazin C, Pfeilschifter J, Vermehren J, Finkelmeier F, Grammatikos G. Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response. Liver Int 2019;39:2174-83. [PMID: 31207039 DOI: 10.1111/liv.14178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
78 Saraiva GN, do Rosário NF, Medeiros T, Leite PEC, Lacerda GS, de Andrade TG, de Azeredo EL, Ancuta P, Almeida JR, Xavier AR, Silva AA. Restoring Inflammatory Mediator Balance after Sofosbuvir-Induced Viral Clearance in Patients with Chronic Hepatitis C. Mediators Inflamm 2018;2018:8578051. [PMID: 29977152 DOI: 10.1155/2018/8578051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
79 Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. J Clin Biochem Nutr 2020;66:245-52. [PMID: 32523252 DOI: 10.3164/jcbn.19-98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
80 Yoh K, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Predictors Associated with Increase in Skeletal Muscle Mass after Sustained Virological Response in Chronic Hepatitis C Treated with Direct Acting Antivirals. Nutrients 2017;9:E1135. [PMID: 29057827 DOI: 10.3390/nu9101135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
81 Mir F, Kahveci AS, Ibdah JA, Tahan V. Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure. Drug Des Devel Ther. 2017;11:497-502. [PMID: 28260862 DOI: 10.2147/dddt.s130945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
82 Tmu N, Kumar A, Sharma P, Singla V, Bansal N, Arora A. Results of Sofosbuvir Plus Ribavirin in Patients With Hepatitis C Related Decompensated Cirrhosis. J Clin Exp Hepatol 2019;9:4-12. [PMID: 30765933 DOI: 10.1016/j.jceh.2018.02.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
83 Joshita S, Sugiura A, Umemura T, Yamazaki T, Fujimori N, Matsumoto A, Usami Y, Tanaka E. Clinical impact of normal alanine aminotransferase on direct-acting antiviral outcome in patients with chronic hepatitis C virus infection. JGH Open 2020;4:574-81. [PMID: 32782941 DOI: 10.1002/jgh3.12296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
84 Persico M, Aglitti A, Aghemo A, Rendina M, Lleo A, Ciancio A, Di Marco V, Lampertico P, Brunetto MR, Zuin M, Andreone P, Villa E, Troshina G, Calvaruso V, Degasperi E, Coco B, Giorgini A, Conti F, Di Leo A, Marzi L, Boccaccio V, Bollani S, Maisonneuve P, Bruno S. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;47:1705-1712. [PMID: 29722439 DOI: 10.1111/apt.14685] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
85 Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. Drugs. 2016;76:1567-1578. [PMID: 27730529 DOI: 10.1007/s40265-016-0648-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 8.6] [Reference Citation Analysis]
86 Nishikawa H, Nishimura T, Enomoto H, Iwata Y, Ishii A, Miyamoto Y, Ishii N, Yuri Y, Takata R, Hasegawa K, Nakano C, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Nishiguchi S, Iijima H. Impact of Virtual Touch Quantification in Acoustic Radiation Force Impulse for Skeletal Muscle Mass Loss in Chronic Liver Diseases. Nutrients 2017;9:E620. [PMID: 28621757 DOI: 10.3390/nu9060620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
87 Hsieh YC, Lee KC, Su CW, Lan KH, Huo TI, Wang YJ, Huang HC, Lin HC, Chu CJ, Huang YH, Hou MC. Persistent liver inflammation in chronic hepatitis C patients with advanced fibrosis after direct-acting antivirals induced sustained virological response. J Chin Med Assoc 2021;84:472-7. [PMID: 33742989 DOI: 10.1097/JCMA.0000000000000517] [Reference Citation Analysis]
88 Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther 2017;46:432-9. [PMID: 28627791 DOI: 10.1111/apt.14177] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
89 Meewan I, Zhang X, Roy S, Ballatore C, O'Donoghue AJ, Schooley RT, Abagyan R. Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega 2019;4:16999-7008. [PMID: 31646247 DOI: 10.1021/acsomega.9b02491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
90 Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38:443-450. [PMID: 28756625 DOI: 10.1111/liv.13534] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
91 Emery JS, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, Wong D, Janssen HLA, Feld JJ. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Am J Gastroenterol. 2017;112:1298-1308. [PMID: 28291241 DOI: 10.1038/ajg.2017.49] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
92 J A, Francis D, C S S, K G A, C S, Variyar EJ. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with Mpro. J Biomol Struct Dyn 2020;:1-12. [PMID: 32873185 DOI: 10.1080/07391102.2020.1813200] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
93 Yen YH, Chen CH, Hung CH, Wang JH, Lu SN, Kee KM, Hu TH. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data. PLoS One 2019;14:e0222605. [PMID: 31581209 DOI: 10.1371/journal.pone.0222605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
94 Nitulescu R, Young J, Saeed S, Cooper C, Cox J, Martel-Laferriere V, Hull M, Walmsley S, Tyndall M, Wong A, Klein MB; Canadian Co-Infection Cohort Study. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals. Int J Drug Policy 2019;65:41-9. [PMID: 30594080 DOI: 10.1016/j.drugpo.2018.08.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
95 Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, Prestileo T, Mazzola G, Di Rosolini MA, Larocca L, Bertino G, Digiacomo A, Benanti F, Guarneri L, Averna A, Iacobello C, Magro A, Scalisi I, Cartabellotta F, Savalli F, Barbara M, Davì A, Russello M, Scifo G, Squadrito G, Cammà C, Raimondo G, Craxì A, Di Marco V, Craxì A, Di Marco V, Cammà C, Calvaruso V, Petta S, Cabbibbo G, Colletti P, Mazzola G, Cascio A, Montalto G, Licata A, Giannitrapani L, Prestileo T, Di Lorenzo F, Sanfilippo A, Ficalora A, Madonia S, Tinè F, Malizia G, Latteri F, Maida M, Cartabellotta F, Vassallo R, Cacciola I, Caccamo G, Maimone S, Saitta C, Squadrito G, Raimondo G, Mondello L, Smedile A, D’andrea S, Bertino G, Ardiri A, Frazzetto E, Rigano G, Montineri A, Larocca L, Cacopardo B, Benanti F, Russello M, Benigno R, Bellia A, Iacobello C, Davì A, Di Rosolini M, Digiacomo A, Fuduli G, Scifo G, Distefano M, Portelli V, Savalli F, Scalici I, Gioia G, Magro A, Alaimo G, Alinovi M, Salvo A, Averna A, Lomonaco F, Guarneri L, Maffeo F, Falzone E, Pulvirenti F. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. Gastroenterology 2018;155:411-421.e4. [DOI: 10.1053/j.gastro.2018.04.008] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 38.3] [Reference Citation Analysis]
96 Zanetto A, Shalaby S, Vitale A, Mescoli C, Ferrarese A, Gambato M, Franceschet E, Germani G, Senzolo M, Romano A, Angeli P, Rugge M, Farinati F, Forton DM, Cillo U, Burra P, Russo FP. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals. Liver Transpl. 2017;23:1103-1112. [PMID: 28544587 DOI: 10.1002/lt.24790] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 8.5] [Reference Citation Analysis]
97 Burra P, Zanetto A. Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation. Transpl Int 2017;30:239-42. [PMID: 28102906 DOI: 10.1111/tri.12917] [Cited by in F6Publishing: 1] [Reference Citation Analysis]